Advanced MRI in the management of adult gliomas

References

• Cairncross J G, Ueki K, Zlatescu M C, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90(19)1473–9
   PubMed Web of Science ®Google Scholar
• Hegi M E, Diserens A C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003
   PubMed Web of Science ®Google Scholar
• Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006; 66: 1661–7
   PubMedGoogle Scholar
• Aghi M, Gaviani P, Henson J W, et al. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005; 11: 8600–5
   PubMed Web of Science ®Google Scholar
• Jenkinson M D, du Plessis D G, Smith T S, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006; 129: 1884–91
   PubMed Web of Science ®Google Scholar
• Megyesi J F, Kachur E, Lee D H, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10: 4303–6
   PubMed Web of Science ®Google Scholar
• Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313–19
   PubMedGoogle Scholar
• Mandonnet E, Delattre J Y, Tanguy M L, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53: 524–8
   PubMed Web of Science ®Google Scholar
• Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006; 60: 380–3
   PubMed Web of Science ®Google Scholar
• Tofts P S, Benton C E, Weil R S, et al. Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Reson Imaging 2007; 25: 208–14
   PubMedGoogle Scholar
• Macdonald D R, Cascino T L, Schold S C, Jr, Cairncross J G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–80
   PubMed Web of Science ®Google Scholar
• Stege E M, Kros J M, de Bruin H G, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005; 103: 802–9
   PubMed Web of Science ®Google Scholar
• Byrne T N. Response of low-grade oligodendroglial tumors to temozolomide. J Neurooncol 2004; 70: 279–80
   PubMedGoogle Scholar
• Preul M C, Caramanos Z, Leblanc R, Villemure J G, Arnold D L. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed 1998; 11(4 – 5)192–200
   PubMedGoogle Scholar
• Nelson S J, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002; 16: 464–76
   PubMed Web of Science ®Google Scholar
• Rabinov J D, Lee P L, Barker F G, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002; 225: 871–9
   PubMed Web of Science ®Google Scholar
• Schlemmer H P, Bachert P, Henze M, et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002; 44(3)216–22
   PubMedGoogle Scholar
• Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002; 20: 343–9
   PubMedGoogle Scholar
• Barbarella G, Ricci R, Pirini G, et al. In vivo single voxel 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS. Int J Oncol 1998; 12: 461–8
   PubMedGoogle Scholar
• Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989–98
   PubMed Web of Science ®Google Scholar
• Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002; 16: 229–37
   PubMed Web of Science ®Google Scholar
• Howe F A, Barton S J, Cudlip S A, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223–32
   PubMed Web of Science ®Google Scholar
• Castillo M, Smith J K, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000; 21: 1645–9
   PubMedGoogle Scholar
• Kuesel A C, Sutherland G R, Halliday W, Smith I C. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994; 7(3)149–55
   PubMedGoogle Scholar
• Barba I, Cabanas M E, Arus C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res 1999; 59: 1861–8
   PubMedGoogle Scholar
• Walecki J, Tarasow E, Kubas B, et al. Hydrogen-1 MR spectroscopy of the peritumoral zone in patients with cerebral glioma: assessment of the value of the method. Acad Radiol 2003; 10: 145–53
   PubMedGoogle Scholar
• Rijpkema M, Schuuring J, Van Der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003; 16: 12–18
   PubMedGoogle Scholar
• Jenkinson M D, Smith T S, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005; 64: 2085–9
   PubMed Web of Science ®Google Scholar
• Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006; 76: 185–91
   PubMed Web of Science ®Google Scholar
• Laprie A, Pirzkall A, Haas-Kogan D A, et al. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 20–31
   PubMed Web of Science ®Google Scholar
• Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516–24
   PubMed Web of Science ®Google Scholar
• Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005; 26: 266–73
   PubMedGoogle Scholar
• Jenkinson M D, Smith T S, Joyce K A, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006; 48(10)703–13
   PubMed Web of Science ®Google Scholar
• Cha S, Knopp E A, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223: 11–29
   PubMed Web of Science ®Google Scholar
• Law M, Oh S, Babb J S, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 2006; 238: 658–67
   PubMed Web of Science ®Google Scholar
• Maia A C, Jr, Malheiros S M, da Rocha A J, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005; 26: 777–83
   PubMedGoogle Scholar
• Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171: 1479–86
   PubMedGoogle Scholar
• Lev M H, Ozsunar Y, Henson J W, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004; 25: 214–21
   PubMed Web of Science ®Google Scholar
• Roberts H C, Roberts T P, Bollen A W, et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001; 8(5)384–91
   PubMedGoogle Scholar
• Xu M, See S J, Ng W H, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005; 56: 919–26, discussion 919 – 26
   PubMed Web of Science ®Google Scholar
• Akella N S, Twieg D B, Mikkelsen T, et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 2004; 20: 913–22
   PubMed Web of Science ®Google Scholar
• Cha S, Knopp E A, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000; 21: 881–90
   PubMed Web of Science ®Google Scholar
• Jager H R, Waldman A D, Benton C, Fox N, Rees J. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 2005; 26: 274–8
   PubMedGoogle Scholar
• Leimgruber A, Ostermann S, Yeon E J, et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006; 64: 869–75
   PubMed Web of Science ®Google Scholar
• Moffat B A, Chen M, Kariaapper M S, et al. Inhibition of vascular endothelial growth factor (VEGF)—a causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 2006; 12: 1525–32
   PubMedGoogle Scholar
• Jackson A, Kassner A, Zhu X P, Li K L. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001; 14: 510–16
   PubMedGoogle Scholar
• Batchelor T T, Sorensen A G, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83–95
   PubMed Web of Science ®Google Scholar
• Mills S J, Patankar T A, Haroon H A, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. AJNR Am J Neuroradiol 2006; 27: 853–8
   PubMedGoogle Scholar
• Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001; 22: 1081–8
   PubMed Web of Science ®Google Scholar
• Fan G G, Deng Q L, Wu Z H, Guo Q Y. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?. Br J Radiol 2006; 79(944)652–8
   PubMedGoogle Scholar
• Tozer D J, Jager H R, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2006; 20(1)49–57
   Google Scholar
• Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9: 53–60
   PubMed Web of Science ®Google Scholar
• Beppu T, Inoue T, Shibata Y, et al. Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol 2005; 63: 56–61, discussion 61
   PubMedGoogle Scholar
• Price S J, Jena R, Burnet N G, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006; 27: 1969–74
   PubMed Web of Science ®Google Scholar
• Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006; 240: 803–10
   PubMedGoogle Scholar
• Jenkinson M D, Smith T S, Brodbelt A R, et al. Apparent diffusion coefficients in oligodendroglial tumours characterised by genotype. J Magn Reson Imaging 2007, (in press)
   Google Scholar
• Chenevert T L, Stegman L D, Taylor J M, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92(24)2029–36
   PubMedGoogle Scholar
• Tomura N, Narita K, Izumi J, et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 2006; 30: 496–500
   PubMedGoogle Scholar
• Hamstra D A, Chenevert T L, Moffat B A, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 2005; 102: 16759–64
   PubMedGoogle Scholar
• Vlieger E J, Majoie C B, Leenstra S, Den Heeten G J. Functional magnetic resonance imaging for neurosurgical planning in neurooncology. Eur Radiol 2004; 14: 1143–53
   PubMed Web of Science ®Google Scholar
• Albayrak B, Samdani A F, Black P M. Intra-operative magnetic resonance imaging in neurosurgery. Acta Neurochir (Wien) 2004; 146: 543–56, discussion 557
   PubMed Web of Science ®Google Scholar
• Berger M S, Rostomily R C. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 1997; 34: 85–101
   PubMed Web of Science ®Google Scholar
• Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 2003; 145: 5–10
   PubMed Web of Science ®Google Scholar
• Nimsky C, Fujita A, Ganslandt O, Von Keller B, Fahlbusch R. Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging. Neurosurgery 2004; 55: 358–370
   PubMed Web of Science ®Google Scholar
• Hirschberg H, Samset E, Hol P K, Tillung T, Lote K. Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg 2005; 48(2)77–84
   PubMedGoogle Scholar